
David C Young

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7649315/publications.pdf Version: 2024-02-01



DAVID C YOUNG

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. Pediatric Pulmonology, 2022, 57, . | 2.0 | 2 |
| 2 | Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. Journal of Cystic Fibrosis, 2022, 21, 339-343. | 0.7 | 35 |
| 3 | Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis. Pediatric Pulmonology, 2022, 57, 2646-2651. | 2.0 | 4 |
| 4 | Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care. Pediatric Pulmonology, 2021, 56, 1378-1385. | 2.0 | 9 |
| 5 | State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatric Pulmonology, 2021, 56, 1825-1837. | 2.0 | 5 |
| 6 | State of the art in cystic fibrosis pharmacology—Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Antiâ€methicillinâ€resistant <i>Staphylococcus aureus</i> (MRSA) antibiotics. Pediatric Pulmonology, 2020, 55, 33-57. | 2.0 | 14 |
| 7 | Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 149-155. | 2.0 | 4 |
| 8 | Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:†II. Therapies for allergic bronchopulmonary aspergillosis. Pediatric Pulmonology, 2020, 55, 3541-3572. | 2.0 | 8 |
| 9 | Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. Pediatric Pulmonology, 2019, 54, 1216-1224. | 2.0 | 16 |
| 10 | An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillinâ€Resistant <i>Staphylococcus aureus</i> . Journal of Clinical Pharmacology, 2019, 59, 198-205. | 2.0 | 15 |
| 11 | Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 15 |
| 12 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update. Pediatric Pulmonology, 2017, 52, 863-865. | 2.0 | 5 |
| 13 | Utilization of antibiotics for methicillinâ€resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 552-559. | 2.0 | 39 |
| 14 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric Pulmonology, 2013, 48, 1047-1061. | 2.0 | 51 |
| 15 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatric Pulmonology, 2013, 48, 1-7. | 2.0 | 15 |
| 16 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric Pulmonology, 2013, 48, 211-220. | 2.0 | 32 |
| 17 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatric Pulmonology, 2013, 48, 107-122. | 2.0 | 46 |
| 18 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric Pulmonology, 2013, 48, 525-537. | 2.0 | 27 |

DAVID C YOUNG

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis. Pharmacotherapy, 2013, 33, 1288-1296. | 2.6 | 41 |
| 20 | Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatric Pulmonology, 2012, 47, 1147-1158. | 2.0 | 35 |
| 21 | A survey of the utilization of antiâ€pseudomonal betaâ€lactam therapy in cystic fibrosis patients. Pediatric Pulmonology, 2011, 46, 987-990. | 2.0 | 39 |